Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Improving Maternal Nutrition in Matlab (IMNiM)

In-home, Intensive Nutrition Counseling to Improve Gestational Weight Gain in Rural Bangladesh: A Cluster-Randomized Controlled Trial

Background: Maternal undernutrition and inadequate gestational weight gain (GWG) are prevalent in rural communities of low- and middle-income countries (LMICs). In Matlab, Bangladesh, 54% of the women fail to gain adequate weight (>4 kg) in the third trimester. Risks associated with inadequate GWG include giving birth to a small-for-gestational age (SGA) infant, low birth weight (LBW) infant, preterm birth (PTB), etc. Few contemporary studies examined the efficacy of nutrition counseling on GWG improvement in LMICs.

Objectives: The primary objective of this study is to assess whether in-home, intensive nutrition counseling during pregnancy, compared to standard antenatal care, could improve GWG among pregnant women in rural Bangladesh.

Methods: This prospective, two-arm, parallel group, equal allocation, open-label, community-based, cluster-randomized controlled trial will be conducted in the icddr,b service area of Matlab, a rural subdistrict of Bangladesh. Clusters will be randomly allocated 1:1 to the intervention arm in which pregnant women will receive monthly in-home, intensive nutrition counseling or the control arm in which pregnant women will receive standard antenatal care as offered by icddr,b and Govt. facilities. Fixed Site Clinics (FSCs) located at the homes of the community health research workers (CHRWs) will act as clusters. Of the 33 FSCs serving rural areas in the icddr,b service area, 20 will be selected randomly and listed. These 20 clinics will then be randomly allocated 1:1 to either an intervention or control group using a computer-generated random allocation sequence. To fulfil the required sample size, each selected CHRW will enroll 16 consecutive pregnancies. Required sample size is 16 women per cluster i.e. 160 women per arm. Eligible participants will be enrolled upon obtaining their consent by 13 and 6/7 weeks of gestation (first trimester) and followed up to 6 weeks postpartum. Trained health workers will visit the homes of the women in the intervention arm once a month and provide nutrition counseling to the women and her influential family members such as mothers, mothers-in-law and husbands. Both intention-to-treat and per-protocol analyses will be performed.

Outcome measures/variables: Proportion of women with inadequate rate of weight gain in the second and third trimester of pregnancy according to the US Institute of Medicine (IOM) 2009 guidelines is the primary outcome variable.

Visão geral do estudo

Status

Ativo, não recrutando

Tipo de estudo

Intervencional

Inscrição (Real)

287

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Chandpur, Bangladesh
        • International Centre for Diarrhoeal Disease Research, Bangladesh

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 39 anos (Adulto)

Aceita Voluntários Saudáveis

Sim

Gêneros Elegíveis para o Estudo

Fêmea

Descrição

Pregnant women permanently residing in the icddr,b service area of Matlab fulfilling the following criteria:

Inclusion Criteria:

  • aged 18-39 years
  • in the first trimester of pregnancy (before 14 weeks of gestation)
  • BMI 16-24.99 kg/m^2 measured on enrollment
  • willing to participate in the study

Exclusion criteria

  • multiple pregnancy (carrying two or more fetuses)
  • threatened abortion, persistent pervaginal bleeding, or cervical incompetence
  • history of three or more consecutive abortions
  • history of gestational diabetes, macrosomia, gestational hypertension, preeclampsia/eclampsia in a prior pregnancy
  • chronic diseases, such as hypertension, heart disease, chronic obstructive pulmonary disease, chronic kidney disease, chronic liver disease, pancreatic diseases, Crohn's disease, ulcerative colitis, diabetes mellitus, thyroid dysfunction, immunological diseases, malignancy or any other diseases which could impede compliance with the study protocol
  • taking medications known to influence fetal growth, such as insulin, thyroid hormones, glucocorticoids
  • known case of serious psychiatric or behavioral disorders, such as schizophrenia, bipolar disorder
  • scored as moderate or worse on enrollment on any one of the subscales of the Depression, Anxiety and Stress Scales-21 (DASS-21)
  • inability to read or write Bengali
  • belonging to moderately or severely food insecure households as measured by the Household Food Insecurity Access Scale (HFIAS)
  • having a plan to move or deliver outside the study area
  • women practicing some form of vegetarianism
  • women belonging to a household from which another woman is already enrolled in the study

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Pesquisa de serviços de saúde
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Intervention
In this arm, pregnant women, along with their influential family members such as mothers, mothers-in-law, and husbands, will receive monthly in-home, intensive nutrition counseling during the prenatal period.
  • Individualized sessions will be conducted by trained health workers following a standard document (counseling booklet)
  • The messages to be provided through the counseling will be contextualized
  • Sessions will start from the early second trimester and repeat monthly until 36 weeks of gestation
  • Counseling sessions will be conducted at the participant's place
  • Sessions will involve influential family members such as the husband, mother-in-law, mother, and the household head along with the pregnant women
  • Women will receive personalized feedback on their dietary intake pattern (dietary diversity) and the rate of weight gain in each session
  • Sessions will be tailored according to each participant's need and progress
Sem intervenção: Control
Pregnant women in this arm will receive standard antenatal care.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
proportion of women with inadequate rate of weight gain in the second and third trimester of pregnancy according to IOM 2009 guidelines
Prazo: Pre-delivery
Pregnancy trimesters are defined as follows: 1st trimester (0 weeks - 13+6 weeks), 2nd trimester (14 completed weeks - 27+6 weeks), and 3rd trimester (28 completed weeks - childbirth). Rate of weight gain between two time points (trimesters) will be calculated by subtracting the weight measured at the first time point from the weight measured at the second time point and dividing the derived value by the difference in weeks between the two time points.
Pre-delivery

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
total gestational weight gain (kg)
Prazo: pre-delivery
pre-delivery
rate of weight gain during the 2nd and 3rd trimester (kg/week)
Prazo: pre-delivery
pre-delivery
proportion of women with inadequate total GWG according to IOM criteria
Prazo: pre-delivery
pre-delivery
proportion of women with inadequate total GWG according to local criteria
Prazo: pre-delivery
pre-delivery
proportion of women with inadequate third trimester weight gain according to local criteria
Prazo: pre-delivery
pre-delivery
proportion of preterm births
Prazo: at delivery
childbirth before 37 completed weeks
at delivery
maternal mid-upper arm circumference (MUAC) (mm)
Prazo: baseline, 36 weeks of gestation, at delivery and 6 weeks post-partum
baseline, 36 weeks of gestation, at delivery and 6 weeks post-partum
maternal weight (kg)
Prazo: baseline, 36 weeks of gestation, pre-delivery, at delivery and 6 weeks post-partum
baseline, 36 weeks of gestation, pre-delivery, at delivery and 6 weeks post-partum
maternal body mass index (BMI) (kg/m^2)
Prazo: baseline, 36 weeks of gestation, pre-delivery, at delivery and 6 weeks post-partum
weight and height (at baseline) will be combined to report BMI
baseline, 36 weeks of gestation, pre-delivery, at delivery and 6 weeks post-partum
infant weight (g)
Prazo: at birth (delivery) and after 4 weeks
at birth (delivery) and after 4 weeks
infant length (cm)
Prazo: at birth (delivery) and after 4 weeks
at birth (delivery) and after 4 weeks
infant head circumference (cm)
Prazo: at birth (delivery) and after 4 weeks
at birth (delivery) and after 4 weeks
proportion of low birth weight (< 2500 g) infants
Prazo: at birth (delivery)
at birth (delivery)
proportion of small for gestational age (<10th percentile) infants according to Intergrowth-21st standards
Prazo: at birth (delivery)
at birth (delivery)
proportion of women with pregnancy complications e.g. anemia, preeclampsia
Prazo: at delivery
at delivery
proportion of women with obstetric complications e.g. induction of labor, caesarean section
Prazo: at delivery
at delivery
newborn Apgar score
Prazo: at birth (delivery)
at birth (delivery)
proportion of infants developing morbidity
Prazo: 4 weeks after birth
4 weeks after birth
proportion of infant mortality
Prazo: 4 weeks after birth
4 weeks after birth
dietary diversity score according to the "Guidelines for Measuring Household and Individual Dietary Diversity"
Prazo: baseline, 36 weeks of gestation and 6 weeks post-partum
score range: 0-9; higher scores indicate a better outcome
baseline, 36 weeks of gestation and 6 weeks post-partum
dietary diversity score according to the "Minimum Dietary Diversity for Women: A Guide to Measurement"
Prazo: baseline, 36 weeks of gestation and 6 weeks post-partum
score range: 0-10; higher scores indicate a better outcome
baseline, 36 weeks of gestation and 6 weeks post-partum
proportion of women with inadequate dietary diversity accroding to the "Minimum Dietary Diversity for Women: A Guide to Measurement"
Prazo: baseline, 36 weeks of gestation and 6 weeks post-partum
score range: 0-10; <5 indicates inadequate dietary diversity
baseline, 36 weeks of gestation and 6 weeks post-partum
energy consumption (kcal)
Prazo: baseline, 36 weeks of gestation and 6 weeks post-partum
baseline, 36 weeks of gestation and 6 weeks post-partum
protein consumption (g)
Prazo: baseline, 36 weeks of gestation and 6 weeks post-partum
baseline, 36 weeks of gestation and 6 weeks post-partum
proportion of women with symptoms of depression as measured by Depression, Anxiety, and Stress Scales-21 (DASS-21) scales
Prazo: baseline, 36 weeks of gestation and 6 weeks post-partum
DASS-21 is a validated, widely used, standardized self-report scale with 7 items in each subscale category of Depression, Anxiety, and Stress symptoms. Responses are scored on a 4-point Likert scale ranging from 0 (did not apply to me at all) to 3 (applied to me very much/most of the time), with higher scores indicating higher levels of depression, anxiety or stress.
baseline, 36 weeks of gestation and 6 weeks post-partum
proportion of women with symptoms of anxiety as measured by Depression, Anxiety, and Stress Scales-21 (DASS-21) scales
Prazo: baseline, 36 weeks of gestation and 6 weeks post-partum
DASS-21 is a validated, widely used, standardized self-report scale with 7 items in each subscale category of Depression, Anxiety, and Stress symptoms. Responses are scored on a 4-point Likert scale ranging from 0 (did not apply to me at all) to 3 (applied to me very much/most of the time), with higher scores indicating higher levels of depression, anxiety or stress.
baseline, 36 weeks of gestation and 6 weeks post-partum
proportion of women with symptoms of stress as measured by Depression, Anxiety, and Stress Scales-21 (DASS-21) scales
Prazo: baseline, 36 weeks of gestation and 6 weeks post-partum
DASS-21 is a validated, widely used, standardized self-report scale with 7 items in each subscale category of Depression, Anxiety, and Stress symptoms. Responses are scored on a 4-point Likert scale ranging from 0 (did not apply to me at all) to 3 (applied to me very much/most of the time), with higher scores indicating higher levels of depression, anxiety or stress.
baseline, 36 weeks of gestation and 6 weeks post-partum
healthcare seeking and services utilization e.g. number of prenatal visits
Prazo: at delivery
at delivery

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: S. M. Tafsir Hasan, MBBS, MS, Nutrition and Clinical Services Division, icddr,b

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

15 de janeiro de 2020

Conclusão Primária (Antecipado)

30 de setembro de 2021

Conclusão do estudo (Antecipado)

31 de outubro de 2021

Datas de inscrição no estudo

Enviado pela primeira vez

28 de dezembro de 2019

Enviado pela primeira vez que atendeu aos critérios de CQ

27 de abril de 2021

Primeira postagem (Real)

3 de maio de 2021

Atualizações de registro de estudo

Última Atualização Postada (Real)

3 de maio de 2021

Última atualização enviada que atendeu aos critérios de controle de qualidade

27 de abril de 2021

Última verificação

1 de abril de 2021

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Ensaios clínicos em In-home, intensive nutrition counseling

3
Se inscrever